Insider buying last 90 days
No open-market insider purchases were filed for GEHC in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every GEHC insider filing, plotted on the chart in Gekko.Open GEHC in Gekko
NASDAQ: GEHC
GE HealthCare Technologies (GEHC) Stock Analysis & Forecast
$64.13−0.31 (−0.5%)
Close on Sep 18, 2026. Page updated Sep 19, 9:16 pm ET.
Gekko Brief
AI summaryGEHC closes at $64.13, down 0.5%, sitting below both its 50-day average of $68.21 and 200-day average of $72.18, with the 50-day below the 200-day. The GekkoIndex reads 73.6, placing the stock in the Buying zone. Against Gekko Fair Value of $101, the price sits 36.5% below that level.
This week's news centers on two threads: corporate development and legal scrutiny. GE HealthCare is reportedly weighing a $1 billion acquisition of Sofie Biosciences, which could extend an existing licensing agreement and add radiotracer rights, manufacturing control, and pharmaceutical diagnostics capability. Separately, BTIG reiterated a Buy rating with a $79.00 price target following feedback on the new Photonova Spectra photon-counting CT system, and the company launched CareIntellect for Operations, an AI tool aimed at predicting hospital operational bottlenecks up to 72 hours ahead. Multiple law firms also disclosed continuing securities fraud investigations into the company, and CFO William K. Grogan received a Form 4 grant of 75,096 shares and 31,877 derivative securities on 14 September 2026.
The next earnings date falls on 4 November 2026, 45 days out and beyond a typical 20-trading-day hold, with the last report on 29 July 2026 showing an EPS beat of $1.06 versus $1.04 estimated and a 9.1% reaction. Over the last 90 days, Congress recorded 5 buys and 0 sells. Analyst consensus across 14 firms shows 9 buy and 5 hold ratings, with a consensus target of $82.50. Seasonally, the next 20 trading days have averaged a 0.6% return over 3 years, rising in 2 of them.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $64.13200-day averageGekko Fair Value $101.00
Key stats
- Market cap
- $28.97B
- P/E ratio
- 14.6
- Forward P/E
- 11.6
- EPS, TTM
- $4.41
- Revenue, TTM
- $21.27B
- Profit margin
- 9.3%
- Dividend yield
- 0.22%
- Beta
- 0.82
- Volume
- 7.60M avg 3.11M
- 1-year return
- −16.3%
- Typical daily move
- ±2.6%
- Typical 20-day move
- ±5.2%
- 50-day average
- $68.21
- 200-day average
- $72.18
- Next earnings
- Nov 4 before open
- Shares outstanding
- 451.7M
GE HealthCare Technologies swing-trade checklist
GE HealthCare Technologies scores 5 supportive, 0 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
5 supportive0 mixed1 headwind
- Trendheadwind
Below 50 and 200-day
Close $64.13 is below the 50-day ($68.21) and 200-day ($72.18) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
73.6, Buying
Reading 73.6 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
36.5% below
Price is 36.5% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 5 buys / 0 sales.
See smart money - Earnings risksupportive
Reports in 45 days
Next report Nov 4, 2026, 45 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+0.6% on average
From this point in the calendar, the next 20 trading days averaged +0.6% over 3 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
GE HealthCare Technologies stock chart and price history
GE HealthCare Technologies closed at $64.13 on Sep 18, 2026, −16.3% over the past year, inside a 52-week range of $58.75 to $89.77.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −14.1%
- 3 months
- +4.1%
- 6 months
- −8.9%
- 1 year
- −16.3%
The full GEHC chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open GEHC in Gekko
Follow GE HealthCare Technologies through every session
Put GEHC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track GEHC in GekkoFree for 7 days. No credit card required.
About GE HealthCare Technologies
GE HealthCare Technologies develops, manufactures and sells medical devices, related services and digital tools used to help diagnose, treat and monitor patients. It is known for its diagnostic imaging equipment, covering molecular imaging, CT, MR, image-guided therapy and X-ray systems, as well as products aimed at women's health. Its customers include healthcare providers across many countries, among them the United States, Canada, several European nations, parts of the Middle East and Africa, China, Taiwan, Mongolia and Hong Kong.
The business is arranged into four segments. Imaging covers advanced scanning technology, while Ultrasound provides devices used in screening, diagnosis and monitoring across areas such as radiology, cardiovascular care, primary care and surgical guidance, including portable units. Patient Care Solutions supplies monitoring equipment, anesthesia and respiratory devices, cardiology tools and maternal-infant care products, alongside related consumables and digital platforms. Pharmaceutical Diagnostics makes contrast agents used before scans like CT and MR, along with radiopharmaceuticals used in PET and SPECT imaging.
GE HealthCare Technologies was established in 2022 and is headquartered in Chicago, Illinois. Its shares are listed on the NASDAQ under the ticker GEHC.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- gehealthcare.com
GE HealthCare Technologies GekkoIndex: the smart money zone
GE HealthCare Technologies’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 73.6, in the Buying zone, up 0.3 points over five sessions.
73.6Buying
Up 0.3 points over five sessions.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 35 | +1.1% | +6.7% | ||
| Accumulation | 234 | +0.3% | 0.0% | ||
| Neutral | 371 | −0.4% | −0.5% | ||
| Distribution | 21 | +2.1% | +2.8% | ||
| Selling | 1 | Too few readings yet | |||
Average GEHC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.2% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the GEHC price, zone by zone.Track GEHC in Gekko
Is GE HealthCare Technologies stock overvalued? Gekko Fair Value
GE HealthCare Technologies trades 36.5% below Gekko Fair Value of $101.00, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what GE HealthCare Technologies shares are worth, recalculated every trading day.
$101.00
Gekko Fair Value, Sep 19, 2026
36.5% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open GEHC in Gekko
GE HealthCare Technologies insider and Congress trading
No open-market insider purchases were filed for GE HealthCare Technologies, and members of Congress disclosed 5 purchases and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
5trades disclosed: 5 purchases and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Aug 12 traded Jul 30 |
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Aug 12 traded Jul 7 |
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Aug 12 traded Jul 6 |
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Aug 12 traded Jul 2 |
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Jul 8 traded Jun 30 |
From congressional disclosures, which report amounts as ranges.
Buybacks
GE HealthCare Technologies has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $200.0M
- As a share of market cap
- 0.69%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds GEHC.
1added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
GE HealthCare Technologies earnings: next date and track record
GE HealthCare Technologies reports on Nov 4, 2026, before the open (45 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected before the open, 45 days away
- EPS estimate
- $1.21
- Revenue estimate
- $5.35B
7 of 8reports beat the EPS estimate
±6.1%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 29, 2026 AI summary
- What they said
- GE HealthCare reported a strong Q2 2026 with record orders and backlog, driven by broad-based demand across segments (Pharmaceutical Diagnostics, Advanced Imaging Solutions) and across geographies. Revenue of $5.3B represented 3.5% organic growth; orders grew 11%, book-to-bill 1.15x, backlog $23.9B. Adjusted EBIT was $750M and adjusted EPS $1.13 (up 6.6%). Management maintained full-year guidance and reiterated medium-term targets. Key positives included traction in new AI-enabled products and recurring service revenue; headwinds concentrated in Patient Care Solutions (PCS) due to fulfillment/supply-chain issues and China market softness. Management emphasized their Heartbeat operating system, innovation pipeline (Photonova, MR, ultrasound, vascular, mammography), pricing and cost actions to offset inflation, and progress on Flyrcado ramp in radiopharmaceuticals.
- Guidance
- Maintained full-year guidance: 3%-4% organic sales growth; adjusted EBIT margin expansion of 10 to 40 bps to 15.4%-15.7%; adjusted EPS $4.80-$5.00 (~5%-9% YoY growth); free cash flow ~ $1.6B for 2026. Q3: organic revenue growth 3%-4% and low double-digit adjusted EPS growth. Reiterated medium-term targets: mid-single-digit organic growth, high-teens to ~20% adjusted EBIT margin, high single-digit to low-double-digit EPS growth, ~90% free cash flow conversion by 2028.
- Risks flagged
- Operational and supply-chain challenges in PCS (component shortages affecting shipment velocity and margins); inflationary pressures (memory chips, oil/freight) with a $250M inflation assumption; China provincial VBP pricing and expected YoY decline in 2026; potential generic competition in contrast media (Amneal) though no current impact; macroeconomic/procedure volume risk; and CFO transition which could introduce near-term leadership risk.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 29, 2026 | $1.06 est $1.04 | $5.30B est $5.26B | +9.1% |
| Apr 29, 2026 | $0.99 est $1.05 | $5.13B est $5.04B | −11.2% |
| Feb 4, 2026 | $1.44 est $1.40 | $5.70B est $5.61B | +4.5% |
| Oct 29, 2025 | $1.07 est $1.05 | $5.14B est $5.09B | −5.5% |
| Jul 30, 2025 | $1.06 est $0.92 | $5.01B est $4.97B | −8.2% |
| Apr 30, 2025 | $1.01 est $0.91 | $4.78B est $4.66B | −0.6% |
| Feb 13, 2025 | $1.45 est $1.26 | $5.32B est $5.33B | +7.3% |
| Oct 30, 2024 | $1.14 est $1.05 | $4.86B est $4.87B | +2.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
GE HealthCare Technologies stock forecast and analyst price targets
Analysts’ average 12-month price target for GE HealthCare Technologies is $82.50, +28.6% from the last close, from 14 firms rating the stock in the last 90 days.
$82.50consensus 12-month target, +28.6% from the last close
Now $64.13Avg $82.50
Low $70High $92
Each firm’s latest rating in the last 90 days: 14 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 14 | Bank of America Securities | $74 | +15.4% |
| Sep 13 | BMO Capital | $71 | +10.7% |
| Aug 25 | Wells Fargo | $85 | +32.5% |
| Aug 19 | BTIG | $79 | +23.2% |
| Aug 13 | Citi | $75 | +16.9% |
+6.7%average 20-day move after past Buying readings
+0.6%average move over the next 20 trading days in the last 3 years
±2.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
GE HealthCare Technologies seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, GE HealthCare Technologies averaged +0.6% across the last 3 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.6% | 2 of 3 |
| Next 10 trading days | +2.1% | 3 of 3 |
| Next 15 trading days | +0.2% | 2 of 3 |
| Next 20 trading days | +0.6% | 2 of 3 |
| Next 30 trading days | −0.3% | 2 of 3 |
For scale, GEHC’s typical 20-trading-day move in either direction is about 5.2%.
GE HealthCare Technologies market cap and key statistics
GE HealthCare Technologies’s market cap is $28.97B, with a P/E ratio of 14.6 and revenue of $21.27B over the last twelve months.
Valuation
- Market cap
- $28.97B
- P/E ratio
- 14.6
- Forward P/E
- 11.6
- EPS, TTM
- $4.41
- Gekko Fair Value
- $101.00
Trading
- Volume
- 7.60M
- Avg volume, 20 days
- 3.11M
- 52-week high
- $89.77
- 52-week low
- $58.75
- Shares outstanding
- 451.7M
Financials
- Revenue, TTM
- $21.27B
- Profit margin
- 9.3%
- Return on equity
- 19.4%
- Quarterly earnings growth, YoY
- +16.8%
Risk and income
- Beta
- 0.82
- Typical daily move
- ±2.6%
- Typical 20-day move
- ±5.2%
- Dividend yield
- 0.22%
GE HealthCare Technologies stock news this week
Coverage of GE HealthCare Technologies this week reads positive: 8 positive, 2 neutral and 2 negative headlines.
- GE HealthCare CFO Grogan William K Granted 31,877 Derivative Securities and 75,096 SharesKalkine Media, Sep 17
- Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law FirmGlobeNewsWire, Sep 17
- GE HealthCare stock maintained at Buy by BTIG on imaging techInvesting.com Canada, Sep 17
- GE HealthCare Technologies Inc. (GEHC) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationGlobeNewsWire, Sep 17
- GE HealthCare (GEHC) Reportedly Eyes $1B Sofie Deal. What Would Ownership Add?Yahoo Finance, Sep 17
- GE HealthCare CFO William K. Grogan Awarded RSUs and Stock Options on September 14, 2026Kalkine Media, Sep 16
GE HealthCare Technologies peers
GE HealthCare Technologies’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 17.1% above |
| ABTAbbott Laboratories | Accumulation | 15.5% below |
| DHRDanaher | Neutral | 1.1% above |
| ISRGIntuitive Surgical | Neutral | 12.3% above |
| MDTMedtronic | Neutral | 24.7% below |
| SYKStryker | Buying | 17.1% below |
A peer links to its own page where one exists.
GE HealthCare Technologies stock FAQ
What is GE HealthCare Technologies’s market cap?
GE HealthCare Technologies’s market cap is $28.97B at the Sep 18, 2026 close of $64.13, with 451.7M shares outstanding. The shares trade on a P/E ratio of 14.6.
What is the GE HealthCare Technologies stock forecast?
The consensus analyst 12-month price target for GE HealthCare Technologies is $82.50, +28.6% from the last close. Of the 14 firms that rated the stock in the last 90 days, 9 rate it a buy, 5 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is GE HealthCare Technologies stock overvalued or undervalued?
On Gekko’s estimate GE HealthCare Technologies is undervalued: the Sep 18, 2026 close of $64.13 is 36.5% below Gekko Fair Value of $101.00. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does GE HealthCare Technologies report earnings next?
GE HealthCare Technologies is expected to report on Nov 4, 2026, before the market opens (45 days away). Analysts expect earnings of $1.21 per share on revenue of $5.35B. GE HealthCare Technologies beat the earnings estimate in 7 of its last 8 reports, moving 6.1% on average across the report.
What is GE HealthCare Technologies’s 52-week high and low?
GE HealthCare Technologies’s 52-week high is $89.77 and its 52-week low is $58.75; it closed at $64.13 on Sep 18, 2026, −16.3% over the past year.
Is GE HealthCare Technologies stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (gekkoindex, fair value, smart money, earnings risk and seasonality) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See GE HealthCare Technologies the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.